Navigation Links
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
Date:8/24/2011

d potentially other biomarkers, in the future.  OncoCEE-BR™ is the only commercially available CTC test that combines enumeration and cytogenetic characterization.

Ron Andrews, CEO of Clarient, said, "Establishing the ability to perform molecular characterization of peripheral cancer cells from a blood sample takes us one step closer to making cancer a chronic disease.  Biocept's OncoCEE™ platform supports our mission of personalized medicine and care for cancer patients."

Biocept's OncoCEE-BR™ test is expected to have application in several clinical settings, including:

  • At the time of recurrence, and especially in cases where a biopsy may be difficult to obtain, to determine if the patient's HER2 status has changed from the original diagnosis or surgery.
  • Confirmation of HER2 status at the time of original diagnosis or surgery, where tumor tissue analysis was negative for HER2 amplification.  Biocept has demonstrated detection of HER2-amplified CTCs in patients with HER2 negative primary tumors, a finding reported by other groups in the scientific literature.  This suggests that the pathologist may have examined a part of the tumor that was not HER2 amplified for a variety of reasons including tumor heterogeneity, and that treatment with HER2-targeted agents may be justified.  This could be a life-changing event for a breast cancer patient.

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is an advanced diagnostic CLIA-certified laboratory services company specializing in the capture, detection, enumeration and molecular analysis of circulating tumor cells (CTCs). Biocept is dedicated to positively impacting the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes innovative and proprietary technologies to deliver clinically relevant an
'/>"/>

SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biocept, Inc. Announces CEO and Director Appointments
2. Biocept, Inc. Announces Two New Director Appointments
3. Biocept, Inc. Announces New Director Appointment - September 28, 2010
4. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
5. Biocept, Inc. Announces New CFO
6. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BR™ Utilizing Circulating Tumor Cells (CTCs)
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
10. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
11. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... LC Sciences LLC, a leading developer ... it is seeking beta testers for the VariantPro™ ... targeted sequencing technology. The system offers cost-effective, minimal ... detection of rare variants. It utilizes novel and ... will collaborate with beta testers to generate test ...
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
(Date:4/16/2015)... April 16, 2015 According to ... involving an outside source was ranked first among ... injuries related to lifting, pushing, pulling, holding, carrying, ... direct costs. The David Round Company takes statistics ... to working hard to develop and design equipment ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... 23 BioDuro and AstraZeneca announced today that ... discovery research for Respiratory and Inflammation indications. BioDuro ... of discovery chemistry, discovery biology, ADMET*, and DMPK** ... discovery and shorten development timelines. "After a successful ...
... Food Industry Professional Lends Experience To Antimicrobial Leader.SHREVEPORT, ... the country,s foremost authorities in the poultry industry, ... years of poultry expertise to SteriFx, a leader ... processing, food safety, healthcare, defense and other industries. ...
... ("BVF") today announced that PROXY Governance, widely recognized as a ... for all BVF Proposals on the GOLD proxy card for ... ) to be held on March 27, 2009.In its report ... (BVF) must clear a high bar to justify a change ...
Cached Biology Technology:BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications 2Dan Blackshear Joins SteriFx Inc. 2Leading Advisory Firm, PROXY Governance, Recommends Avigen Shareholders Vote on GOLD Card to Remove Incumbent Directors and Elect BVF's Stockholder-Oriented Nominees 2
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... changes to a gene that do not alter ... bipolar disorder. This is the first epigenome-wide investigation ... be a significant step on the journey to ... senior scientist in the Krembil Family Epigenetic Laboratory ...
... WALL, N.J., March 10 BIO-key International,Inc. (OTC Bulletin Board: ... 2007 financial results on Monday, March 17, 2008,after the market ... call, which will be broadcast live over the Internet,on Tuesday, ... What: BIO-key International, Inc. Fourth Quarter and Full ...
... Bethesda, MD A new and notable article ... Narrow Pore appears in Volume 94, Issue 5, of ... Passage Times for Polymer Translocation Pulled through ... through a nanometer-sized pore in membranes, in a process ...
Cached Biology News:Epigenetic changes discovered in major psychosis 2BIO-key(R) Announces Fourth Quarter and Full Year 2007 Earnings Release and Conference Call Schedule 2Media highlights for February in Biophysical Journal 2
Special grade: for electrophoresis...
... DAPI (4,6-diamidine-2-phenylindole, dihydrochloride) is ... the nucleus blue in color. ... excellent contrast to red fluorochromes ... Red, or R-Phycoerythrin. DAPI can ...
Contact us for more information...
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Biology Products: